Skip to main content
Retour
Watch Compare

Elicio Therapeutics, Inc.

Qualité des données : 83%
ELTX
Nasdaq Manufacturing Chemicals
10,28 €
▲ 0,15 € (1,48%)
Cap. Boursière: 189,11 M
Prix
10,28 €
Cap. Boursière
189,11 M
Fourchette du Jour
10,02 € — 10,89 €
Fourchette 52 Semaines
4,61 € — 14,93 €
Volume
71 777
Ouverture 10,07 €
Moyenne 50J / 200J
10,18 €
1,00% above
Moyenne 50J / 200J
9,56 €
7,48% above

Quick Summary

Points Clés

Debt/Equity of 2,55 — high leverage
Negative free cash flow of -36,97 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-1400,74%
En dessous de la moyenne du secteur (-53,47%)
ROIC-144,02%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
2,55
Au-dessus de la moyenne du secteur (0,31)
Current Ratio3,29
Interest Coverage-33,29

Valorisation

PE (TTM)
-4,78
En dessous de la moyenne du secteur (-1,47)
P/B Ratio49,56
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -4,8 -1,5
P/B 49,6 1,6
ROE % -1400,7 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E 2,6 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -39,57 M
ROE -1400,74% ROA -136,90%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -36,97 M
ROIC -144,02% FCF Growth (3Y) N/A
Safety
Debt / Equity 2,55 Current Ratio 3,29
Interest Coverage -33,29 Asset Turnover N/A
Working Capital 14,95 M Tangible Book Value 3,82 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,78 Forward P/E N/A
P/B Ratio 49,56 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -19,55%
Market Cap 189,11 M Enterprise Value 178,22 M
Per Share
EPS (Diluted TTM) -2,58 Revenue / Share N/A
FCF / Share -2,01 OCF / Share -2,01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 93,42%
SBC-Adj. FCF -39,21 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — 2,30 M 28,31 M
Net Income -39,57 M -51,90 M -35,20 M -38,81 M -54,57 M
EPS (Diluted) -2,58 -4,25 -6,96 -1,29 -1,93
Gross Profit — — — — —
Operating Income -37,71 M -44,99 M -35,75 M -39,62 M -39,31 M
EBITDA — — — — —
R&D Expenses 24,90 M 33,66 M 23,85 M 18,10 M 48,70 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 1,13 M 455 000,0 1,06 M 805 000,0 -1,85 M
Income Tax 0,0 0,0 0,0 11 000,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 25,86 M 28,18 M 27,15 M 52,79 M 96,51 M
Total Liabilities 24,23 M 39,49 M 15,77 M 9,02 M 15,01 M
Shareholders' Equity 1,64 M -11,31 M 11,37 M 43,77 M 81,51 M
Total Debt 10,00 M — — — 0,0
Cash & Equivalents 18,56 M 17,62 M 12,89 M 50,49 M 88,76 M
Current Assets 19,31 M 20,69 M 16,35 M 51,43 M 91,25 M
Current Liabilities 8,11 M 11,52 M 9,77 M 6,37 M 11,30 M